Do GLP-1 drugs cause suicidal thoughts? What the evidence shows

The short answer

The strongest evidence available, pooled randomized trials in more than 81,000 people, does not show that GLP-1 medications such as Ozempic, Wegovy, or Mounjaro cause suicidal thoughts. In early 2026 the FDA asked drugmakers to drop the suicidal-thoughts warning from several weight-loss labels.

If you started a GLP-1 medication and later saw headlines tying these drugs to suicidal thoughts, the worry makes sense. The warning on the label was real, and so was the investigation behind it. Here is what the trial evidence actually found, why three major regulators reached the same answer, and the mood changes that are still worth watching for.

Where the suicidal-thoughts warning came from

In the middle of 2023, a small number of reports from Iceland described suicidal thoughts and self-harm in people taking semaglutide (the ingredient in Ozempic and Wegovy) and liraglutide (the ingredient in Saxenda). European regulators took the reports seriously and opened a formal review in July 2023.

It helps to know what those reports are. They come from spontaneous safety databases, where doctors, patients, and companies flag events that happen while someone is on a drug. That kind of report can raise a question, but it cannot answer it. The database records that an event happened during treatment, not that the treatment caused it. People start GLP-1 medications at a point in life when weight, health, and mood are often already under strain, and heavy media attention tends to increase reporting on its own. So the right response to a signal like this is not panic and not dismissal. It is to go and look at the controlled data.

What the largest trial analysis actually found

The cleanest evidence comes from randomized controlled trials, where people are assigned to the drug or a comparator by chance, so the two groups start out alike. A 2025 meta-analysis in the Journal of Diabetes pooled 25 of these trials with more than 81,000 participants, over 42,000 on a GLP-1 receptor agonist and over 39,000 on a comparator. Twenty trials studied type 2 diabetes, five studied obesity, and four included adolescents under 18.

Across all of them, there was no significant difference in suicidal behavior between the GLP-1 group and the comparison group (relative risk 0.84, 95% confidence interval 0.54 to 1.32). The statistical heterogeneity was zero, meaning the trials pointed in a consistent direction. Broken out by specific outcome, the picture held:

• Suicidal ideation: no higher risk (relative risk 1.04, 95% confidence interval 0.48 to 2.25, across 12 trials).
• Suicide attempts: no higher risk, and the point estimate leaned lower (relative risk 0.68, 95% confidence interval 0.31 to 1.45, across 13 trials).
• Completed suicide: no higher risk (relative risk 1.06, 95% confidence interval 0.38 to 2.92, across 6 trials).
• Depression-related suicide: no higher risk (relative risk 0.65, 95% confidence interval 0.16 to 2.71, across 7 trials).

The result did not change when the researchers split the data. It looked the same in diabetes trials (0.74) and obesity trials (1.07), in adults and in adolescents, and across the individual drugs, including semaglutide (0.82), liraglutide (0.92), dulaglutide (0.46), and exenatide (0.98). A test for publication bias came back clean.

Now the honest part, because it matters. Suicide is, thankfully, rare, and rare events are hard to study even in 81,000 people. The confidence intervals above are wide and cross 1, and the authors say plainly that statistical power stays limited for rare outcomes like these. A few of the included trials were also rated at higher risk of bias because they were not fully blinded, and only English-language studies were counted. So the fair reading is "no signal of harm in the best data we have," not "proven impossible." That is a meaningful difference, and it is the kind of calibration worth holding onto when a single frightening headline lands.

Why a database headline can say the opposite

You may still run into reports that sound alarming, and they are not made up. One analysis of the World Health Organization's global adverse-event database found that people taking semaglutide had about a 45% higher rate of reported suicidal thoughts compared with all other drugs in the database. That is exactly the kind of spontaneous-reporting signal that started the review in the first place.

The trouble is that this type of database cannot separate the drug from everything else going on, and reporting itself spikes once a story is in the news. When researchers looked at more controlled comparisons, the signal faded. Data published in the BMJ in early 2025 found no increased suicidality with GLP-1 drugs compared with other diabetes drug classes such as DPP-4 inhibitors and SGLT2 inhibitors. When a well-conducted trial analysis and a spontaneous-report tally disagree, the trial analysis carries more weight on the question of cause.

What regulators decided

Three agencies reviewed the same body of evidence and arrived at the same place, though they chose their words carefully.

The European Medicines Agency finished its review in April 2024. Its safety committee concluded that the available evidence does not support a causal link between GLP-1 receptor agonists and suicidal or self-injurious thoughts, and it said no change to the product information was needed. The UK's medicines regulator reached the same conclusion. Much of the weight came from large studies of semaglutide users that found a lower, not higher, rate of suicidal ideation than users of other medicines.

The FDA moved more cautiously and more slowly. Its early 2024 look found no clear link but stopped short of ruling out a small risk. Its final review came on January 13, 2026, and pooled 91 trials with 107,910 participants. The agency reported no increased risk of suicidal thoughts or behavior, and no rise in anxiety, depression, irritability, or psychosis, and it asked the makers of Saxenda, Wegovy, and Zepbound to remove the suicidal-ideation warning from those labels. Worth noting: the FDA framed this as not finding an increased risk rather than issuing a clean bill of health, and it said doctors should keep watching patients for mood changes. The diabetes versions of these drugs never carried the warning in the first place.

What this means for you, and the mood changes worth watching

For most people the takeaway is reassuring: the suicidal-thoughts fear that drove the old warning is not supported by the controlled evidence, and the label change reflects that. Reassuring is not the same as "mood never matters," though, and it would be dishonest to pretend otherwise.

Some people do notice real changes on a GLP-1 medication. A flattening of emotion, sometimes nicknamed the "Ozempic personality," shows up in anecdotes more than in trial data. Rapid weight loss and the life changes around it can stir up mood on their own. And there is a quieter, more fixable factor that often gets missed. When you eat much less, you can slide into nutrient deficiency on GLP-1, and low vitamin B12, vitamin D, iron, and magnesium are all tied to low mood and flat energy. If you feel persistently drained or down, that is a reason to check your nutrient status, not to assume the worst about the drug. Our guide to which vitamins to take and monitor on GLP-1 walks through the labs worth running, and the broader piece on GLP-1 medications and mood goes deeper on the emotional side. For context on where this sits among the other known GLP-1 side effects, the full overview helps.

Covering those nutrient gaps is the job GLP-1 Shield was built for. To be clear about what a supplement can and cannot do: closing a B12 or vitamin D gap can protect your energy and steady your baseline, but no supplement treats a mental health condition, and none should be used in place of care. GLP-1 medications are prescription-only, and any decision to start, change, or stop one belongs with your prescriber.

One line that is not optional: if you ever have thoughts of harming yourself, do not wait and do not try to reason it out alone. In the US you can call or text 988 to reach the Suicide and Crisis Lifeline, any hour of the day, or contact your doctor or local emergency services. New or worsening thoughts of self-harm, a sudden drop in mood, or losing interest in things you normally care about are all worth raising with your prescriber right away, especially if you have a history of depression or anxiety.

Frequently asked questions

Do Ozempic and Wegovy cause suicidal thoughts?

The best available evidence says no. A 2025 meta-analysis of 25 randomized trials in more than 81,000 people found no higher risk of suicidal behavior with GLP-1 drugs versus comparators (relative risk 0.84). Because suicide is rare, the data cannot be called perfect, but there is no signal of harm, and semaglutide (Ozempic and Wegovy) showed a relative risk of 0.82.

Did the FDA remove the suicide warning from weight-loss drugs?

Yes. On January 13, 2026, after reviewing 91 trials with 107,910 participants and finding no increased risk, the FDA asked the makers of Saxenda, Wegovy, and Zepbound to remove the suicidal-ideation warning from those labels. The diabetes versions of these drugs never carried the warning.

Can semaglutide affect your mood?

Some people report mood changes or emotional flattening on semaglutide, though this is seen more in anecdotes than in controlled trials. Rapid weight loss and nutrient gaps can also affect mood. Persistent low mood is worth raising with your prescriber rather than waiting it out.

Should I stop my GLP-1 if I feel depressed?

Not on your own. Talk to your prescriber, who can look at whether the drug, a nutrient deficiency, or something else is driving it. If you have any thoughts of self-harm, treat it as urgent and call or text 988 in the US, or contact emergency services now.